Liquid Encapsulation Utilizing An Emulsion Or Dispersion To Form A Solid-walled Microcapsule (includes Liposome) Patents (Class 264/4.1)
-
Patent number: 11001541Abstract: The present invention relates to methods of preparing purified cyclopropylene (1-methylcyclopropylene) gas employing one or more non-reactive purification processes to purify substances including, without limitation, cyclopropene (1-methylcyclopropylene) gas and/or lithio-cyclopropene.Type: GrantFiled: August 13, 2019Date of Patent: May 11, 2021Inventor: Nazir Mir
-
Patent number: 10987308Abstract: Disclosed are targeted sub-50 nanometer nanoparticles suitable for delivering bioactive agents of interest, and related compositions, methods, and systems, which improve the manufacturing, stability, efficacy and other aspects of therapeutic nanoparticles.Type: GrantFiled: September 3, 2015Date of Patent: April 27, 2021Assignee: GENESEGUES, INC.Inventor: Gretchen M. Unger
-
Patent number: 10988633Abstract: The invention aims to provide a novel compound to be suitably used for antifouling agents. The compound of the invention is represented by the following formula (1): wherein R1 is a monovalent organic group containing a polyether chain; X1 and X2 are each individually a monovalent group; and the polyether chain is a chain represented by the following formula: —(OC6F12)m11—(OC5F10)m12—(OC4F8)m13—(OC3X106)m14—(OC2F4)m15—(OCF2)m16—, wherein m11, m12, m13, m14, m15, and m16 are each individually an integer of 0 or 1 or greater; X10s are each individually H, F, or Cl; and the repeating units are present in any order.Type: GrantFiled: September 22, 2017Date of Patent: April 27, 2021Assignee: DAIKIN INDUSTRIES, LTD.Inventors: Tsuneo Yamashita, Masatoshi Nose, Hisashi Mitsuhashi, Saya Nii, Eiji Sakamoto, Kaori Ozawa
-
Patent number: 10981994Abstract: The present invention relates to antibodies and antigen-binding fragments thereof that bind to PD-1, and to methods of using such antibodies and antigen-binding fragments. For example, the present invention provides humanized anti-PD-1 antibodies and methods of use thereof.Type: GrantFiled: August 12, 2019Date of Patent: April 20, 2021Assignee: Apollomics Inc.Inventors: Junzhuan Qiu, Ziyong Sun, Jiping Zha
-
Patent number: 10968271Abstract: The present invention relates to amino acid sequences that are directed against Interleukin-23 (IL-23). The amino acid sequences of the present invention comprise two NANOBODIES® against IL-23 and one NANOBODY® against serum albumin, linked by two linkers (9GS linkers). In particular, the invention relates to the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3 (listed in Table 1 and FIG. 1) (also referred to herein as “anti-IL 23 polypeptides of the invention”).Type: GrantFiled: October 28, 2016Date of Patent: April 6, 2021Assignee: Ablynx N.V.Inventor: Marie-Ange Buyse
-
Patent number: 10947303Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: GrantFiled: July 26, 2018Date of Patent: March 16, 2021Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH, LTD.Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
-
Patent number: 10941057Abstract: A particle for emulating pollutant tracking in water has a florescent core. A semitransparent shell is formed around the florescent core.Type: GrantFiled: June 28, 2018Date of Patent: March 9, 2021Assignee: U.S. Environmental Protection AgencyInventor: Anthony Todd Zimmer
-
Patent number: 10913882Abstract: The method for low temperature microencapsulation of phase change materials or other components includes the following steps: (a) preparing a phase change emulsion including droplets of at least one active phase-change material in water with a surfactant; (b) adding a monomer of at least one encapsulating agent; (c) introducing the phase change emulsion into a UV reactor while stirring the emulsion; and (d) initiating the photo polymerization of monomers using at least one UV lamp inside the UV reactor for photo polymerization until the phase change material is encapsulated within a polymeric shell to form microcapsules. The microcapsules obtained by this process may have a diameter between about 0.5 to about 2 ?m. Other sizes can also be obtained by changing stirring speed of the emulsion.Type: GrantFiled: August 31, 2016Date of Patent: February 9, 2021Assignees: QATAR UNIVERSITY, COLLEGE OF THE NORTH ATLANTIC-QATAR, AUCKLAND UNISERVICES LIMITEDInventors: Mohammed Farid, Refat Al Shannaq, Shaheen Al-Muhtaseb, Jamal Kurdi
-
Patent number: 10898435Abstract: Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase.Type: GrantFiled: July 15, 2019Date of Patent: January 26, 2021Assignee: FUJIFILM CorporationInventors: Makoto Ono, Kohei Ono, Takeshi Matsumoto, Mikinaga Mori
-
Patent number: 10881100Abstract: An aqueous suspoemulsion, characterized in that it contains at least the two components: (a) a dispersed oil phase comprising: (i) lambda-cyhalothrin as the first active ingredient, and (ii) at least one C9-C10 aromatic hydrocarbon solvent having lambda-cyhalothrin dissolved therein; (b) a continuous water phase containing: (i) at least one water-insoluble second active ingredient which is suspended in the continuous phase; and (ii) a dispersing agent in an amount sufficient to disperse the water-insoluble active ingredient. Methods of making and using this suspoemulsion are also disclosed.Type: GrantFiled: January 29, 2014Date of Patent: January 5, 2021Assignee: ROTAM AGROCHEM INTERNATIONAL COMPANY LIMITED CHAI WANInventor: James Timothy Bristow
-
Patent number: 10870690Abstract: The present invention relates to compositions for treating cancer by having one or more activities of inhibiting cancer growth, inhibiting cancer cell invasion, and inhibiting cancer recurrence.Type: GrantFiled: May 31, 2017Date of Patent: December 22, 2020Inventor: Yihong Zhou
-
Patent number: 10857080Abstract: Lipid microcapsules are described that can include at least one lipophilic active substance, more specifically a retinoid, in a soluble form. Also described, are pharmaceutical compositions including the same and a method for the production thereof. Methods of using such a composition to treat dermatological pathologies are also described.Type: GrantFiled: December 4, 2014Date of Patent: December 8, 2020Assignee: GALDERMA RESEARCH & DEVELOPMENTInventors: Claire Mallard, Carole Dubayle
-
Patent number: 10842721Abstract: Purified polyurea capsules that encapsulate active materials for use in personal care, fine fragrance, or deodorant products are provided as are methods for producing the same.Type: GrantFiled: January 16, 2019Date of Patent: November 24, 2020Assignee: INTERNATIONAL FLAVORS & FRAGRANCES INC.Inventors: Yabin Lei, Li Xu, Carol Joyce, Lewis Michael Popplewell
-
Patent number: 10835577Abstract: The present invention relates to novel peptides derived from Kita-kyushu lung cancer antigen (CT83), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.Type: GrantFiled: November 23, 2016Date of Patent: November 17, 2020Assignee: IMMUNOCORE LIMITEDInventors: Alex Powlesland, Chandramouli Chillakuri, Dhaval Sangani, Graham Hood, Alina Popa
-
Patent number: 10835606Abstract: The present invention relates to a conjugate comprising an anti-EGFR1 antibody or an EGFR binding fragment thereof and at least one dextran derivative, wherein the dextran derivative comprises at least one D-glucopyranosyl unit, wherein at least one carbon selected from carbon 2, 3 or 4 of the at least one D-glucopyranosyl unit is substituted by a substituent of the formula —O—(CH2)”—S—Bi2Hii2? wherein n is in the range of 3 to 10; and the dextran derivative is bound to the anti-EGFR antibody or an EGFR1 binding fragment thereof via a bond formed by a reaction between at least one aldehyde group formed by oxidative cleavage of a D-glucopyranosyl unit of the dextran derivative and an amino group of the anti-EGFR1 antibody or an EGFR1 binding fragment thereof.Type: GrantFiled: April 15, 2019Date of Patent: November 17, 2020Assignee: Tenboron OyInventors: Anne Leppanen, Filip S. Ekholm, Jari Helin, Hanna Salo, Anne Kanerva
-
Patent number: 10824822Abstract: A method, system, and mobile terminal configured for medication management are provided. A read operation is performed by a magnetic reader to detect whether a pattern of bio-compatible nano-magnetic particles on a pill is present within a body of a patient. Information from the read operation is transmitted to a mobile terminal by the wireless transceiver.Type: GrantFiled: February 5, 2019Date of Patent: November 3, 2020Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATIONInventors: Rajeev Narayanan, Bing Dang, Bo Wen
-
Patent number: 10807060Abstract: A method for preparing solid microcapsules, comprising the steps of adding under agitation a composition C1 comprising at least one active material to a cross-linkable liquid composition C2, the active material is not an additive to be used in the lubricant, fuel or bitumen industries, drilling sludges or muds, or oil exploration/production, compositions C1 and C2 being immiscible with each other. A first emulsion is obtained comprising droplets of composition C1 dispersed in composition C2, adding under agitation the first emulsion to a liquid composition C3, composition C3 and composition C2 being immiscible with each other, to obtain a second emulsion comprising droplets dispersed in composition C3.Type: GrantFiled: September 16, 2016Date of Patent: October 20, 2020Assignee: CALYXIAInventors: Jamie Walters, Damien Demoulin, Jérôme Bibette
-
Patent number: 10799619Abstract: Hydrogels and composite material containing hydrogels and liposomes dispersed therein, which exhibit a reduced friction coefficient compared to neat hydrogels or composites containing hydrogels, processes for preparing the same, and methods for using the same are disclosed.Type: GrantFiled: April 18, 2019Date of Patent: October 13, 2020Assignee: Yeda Research and Development Co. Ltd.Inventors: Jacob Klein, Ronit Goldberg, Noa Iuster, Raya Sorkin
-
Patent number: 10799461Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.Type: GrantFiled: January 12, 2018Date of Patent: October 13, 2020Assignee: ENGENEIC MOLECULAR DELIVERY PTY LTDInventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
-
Patent number: 10772807Abstract: Lipid microcapsules are described that can include at least one irritant active substance, more specifically a retinoid, in a soluble form. Also described, are pharmaceutical compositions comprising the same, and methods for the production thereof. A method of using the composition to treat dermatological pathologies is also described.Type: GrantFiled: December 4, 2014Date of Patent: September 15, 2020Assignee: GALDERMA RESEARCH & DEVELOPMENTInventors: Claire Mallard, Carole Dubayle
-
Patent number: 10759832Abstract: Peptides having a human minute binding protein-2 (HDM-2) targeting sequence that target the human minute binding protein-2, fusion proteins having a HDM-2 targeting sequence, and methods of using the peptides and proteins to treat cancer are described.Type: GrantFiled: June 28, 2019Date of Patent: September 1, 2020Assignee: SLH Innovations LLCInventor: Matthew R. Pincus
-
Patent number: 10759843Abstract: The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO:1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.Type: GrantFiled: October 16, 2018Date of Patent: September 1, 2020Inventors: Santos Susin, Pierre Launay, Philippe Karoyan, Helene Merle-Beral
-
Patent number: 10736845Abstract: A pharmaceutical composition can include a plurality of liposomes comprising docetaxel and doxorubicin. In various embodiments, a liposome can include (i) an active pharmaceutical ingredient (API) comprising docetaxel and doxorubicin; (ii) a lipid layer comprising an unsaturated phospholipid, a cholesterol, a cationic lipid, and preferably a pegylated phospholipid; and (iii) an aqueous interior, wherein the docetaxel is in the lipid layer and the doxorubicin is crystallized in the aqueous interior. The liposomes can be used to treat a subject, for example, a human subject having cancer. The cancer can be, for example, a lung cancer, preferably non-small cell lung cancer (NSCLC), colon cancer, breast cancer, or liver cancer.Type: GrantFiled: March 3, 2016Date of Patent: August 11, 2020Assignee: Cureport Inc.Inventors: De-Min Zhu, Guoqiang Chen
-
Patent number: 10729748Abstract: Undue scarring of healing wounds is decreased and/or the relapse rate of wounds is lowered by applying a composition that includes hemoglobin to the wound area. At least 90% of the hemoglobin in the composition is provided in CO-charged form.Type: GrantFiled: February 29, 2016Date of Patent: August 4, 2020Assignee: MÖLNLYCKE HEALTH CARE ABInventor: Michael Sander
-
Patent number: 10723765Abstract: ?-Hairpin peptidomimetics of the general formula cyclo(-Xaa1-Xaa2-Thr3-Xaa4-Ser5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-) and pharmaceutically acceptable salts thereof, with Xaa1, Xaa2, Xaa4, Xaa6, Xaa7, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12 and Xaa13 being amino acid residues which are defined in the description and the claims, have elastase inhibitory properties, especially against human neutrophil elastase, and can be used for preventing infections or diseases related to such infections in healthy individuals or for slowing infections in infected patients. The compounds of the invention can further be used where cancer, or immunological diseases, or pulmonary diseases, or cardiovascular diseases, or neurodegenerative diseases, or inflammation, or diseases related to inflammation, are mediated or resulting from elastase activity. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.Type: GrantFiled: December 27, 2013Date of Patent: July 28, 2020Assignee: POLYPHOR AGInventors: Frank Otto Gombert, Daniel Obrecht, Odile Sellier-Kessler
-
Patent number: 10723780Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: GrantFiled: March 19, 2019Date of Patent: July 28, 2020Assignees: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Genady Kostenich, Mor Oron-Herman, Arie Orenstein, Talia Shekhter Zahavi, Ehud Gazit, Yoseph Salitra, Ludmila Buzhansky
-
Patent number: 10716774Abstract: Isotretinoin compositions having improved bioavailability are disclosed. The compositions are oral formulations containing isotretinoin, a lipid excipient and a cosolvent, wherein the ratio of isotretinoin to the lipid excipient is from about 1:1.2 to about 1:1.6. The compositions can be in the form of a pharmaceutically acceptable oral dosage form such as a capsule or compressed tablet wherein the isotretinoin is adsorbed onto blended particles of a cellulosic polymer and silicon dioxide in combination with a lipid excipient such as soy phosphatidylcholine and a cosolvent such as propylene glycol. Methods of preparing the compositions and methods of treatment using the compositions are also disclosed.Type: GrantFiled: January 3, 2019Date of Patent: July 21, 2020Assignee: YALE PHARMACEUTICALS LLCInventor: Basavaraj Siddalingappa
-
Patent number: 10687541Abstract: Coconut oil, coconut oil blends that are high in MCTs such as LouAna® liquid coconut oil, pure MCT oils, and Omega-3 oils may be emulsified to create an emulsified oil or blend that may take the form of a creamy shot or a cream substitute. These oils and/or blends may be emulsified using an emulsifier that may be selected from the following: sunflower lecithin, sodium stearoyl lactylate (SSL), or a combination of sunflower lecithin and SSL. By emulsifying these oils/oil blends, a good tasting creamy shot or a cream substitute can be formed.Type: GrantFiled: October 11, 2017Date of Patent: June 23, 2020Inventor: Jesse Windrix
-
Patent number: 10653735Abstract: Use of Mesembryanthemum crystallinum L. callus extract in the manufacture of a medicament or a skin care product, wherein the medicament or skin care product is for at least one of delaying skin cell aging, nursing skin, repairing skin, treating skin cancer, and preventing skin cancer.Type: GrantFiled: March 17, 2017Date of Patent: May 19, 2020Assignee: TCI CO., LTD.Inventors: Yung-Hsiang Lin, Wei-Wen Kuo, I-Hui Chen, Yi-Chun Chen, Hui-Hsin Shih, Yun-Ching Tsai
-
Patent number: 10653786Abstract: Provided herein relates to compositions and methods for lubrication of a surface. The surface amenable to the compositions and methods described herein can be a non-biological surface, a biological surface, or a combination thereof. In some embodiments, the composition comprising a phospholipid-coated silk microsphere can be used for lubrication of a surface. In some embodiments, the composition comprising a phospholipid-coated silk microsphere can be used for joint lubrication, e.g., for treatment of joint disorders such as arthritis.Type: GrantFiled: April 25, 2013Date of Patent: May 19, 2020Assignees: TRUSTEES OF TUFTS COLLEGE, Tulane Educational FundInventors: David L. Kaplan, Xiaoqin Wang, Vijay John, Noshir Pesika, Rubo Zheng
-
Patent number: 10640565Abstract: The present invention provides novel humanized anti-human C-C chemokine receptor type 7 (CCR7) antibodies and compositions comprising such antibodies. The antibodies and compositions are useful in the treatment of a cancer of which the tumour cells express a CCR7 receptor, in the treatment of inflammatory conditions, conditions or complications arising from tissue or organ transplantations, and conditions or complications arising from or associated with fibrosis. The invention further provides nucleic acid molecules encoding the anti-CCR7 antibodies, cells expressing the anti-CCR7 antibodies and methods for producing the anti-CCR7 antibodies.Type: GrantFiled: August 10, 2016Date of Patent: May 5, 2020Assignee: PepMab B.V.Inventors: Jaap Willem Back, Ronald Boshuizen, Wouter Cornelis Puijk, Johan Turkstra, Klaus Heinrich Schwamborn
-
Patent number: 10639348Abstract: The peptides of the invention are of formula (I) or (IV). The peptides of the invention are useful in the treatment of cancer.Type: GrantFiled: March 15, 2017Date of Patent: May 5, 2020Assignee: IDP DISCOVERY PHARMA, S.L.Inventors: Santiago Esteban Martín, Laura Nevola
-
Patent number: 10617128Abstract: Coconut oil, coconut oil blends that are high in MCTs such as LouAna® liquid coconut oil, pure MCT oils, Omega-3oils, cannabidiol (CBD), hemp extract, tree nut oil, macadamia oil, almond oil, cashew oil, avocado oil, docosahexaenoic acid (DHA), fish oil, and/or conjugated linoleic acid (CLA) may be emulsified to create an emulsified oil or blend that may take the form of a creamy shot or a cream substitute. These oils and/or blends may be emulsified using an emulsifier that may be selected from the following: sunflower lecithin, sodium stearoyl lactylate (SSL), acacia gum, beta-cyclodextrin, and combinations of same. By emulsifying these oils/oil blends, a good tasting creamy shot or a cream substitute can be formed.Type: GrantFiled: October 11, 2018Date of Patent: April 14, 2020Inventor: Jesse Windrix
-
Patent number: 10611797Abstract: A peptide binding to transcription factor CP2c, having an activity of preventing and treating cancer and represented by SEQ ID NO: 1: Asn-Tyr-Pro-Gln-Arg-Pro, and a pharmaceutical composition and a dietary supplement composition for preventing and treating cancer, both of which contain the same as an active ingredient are disclosed. When cancer cells are treated with the peptide and the pharmaceutical composition containing the same, the peptide can specifically bind to CP2c by passing, with very high stability, through the cell membrane and can inhibit the DNA binding ability of CP2c, thereby disturbing CP2c-mediated cancer cell-specific transcriptional activity through the inhibition of CP2c activity. Thus, the peptide and pharmaceutical composition containing the same can be effectively used for specifically treating only cancer cells and can be utilized for cancer prevention and as a dietary supplement additive therefor.Type: GrantFiled: March 29, 2016Date of Patent: April 7, 2020Assignee: IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)Inventors: Chul Geun Kim, Min Young Kim, Chan Gil Kim, Ho Chul Kang, Ji Hyung Chae, Su Jae Lee, Eun Jung Baek, Chae Ok Yun, Jin Won Lee, Young Su Lim, Je Min Choi, Dae Hyun Ha, Hyung Sik Won, Seung Han Son
-
Patent number: 10548841Abstract: The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization.Type: GrantFiled: August 15, 2013Date of Patent: February 4, 2020Assignee: OPKO Pharmaceuticals, LLCInventors: Arturo Santos, Phillip Frost
-
Patent number: 10543274Abstract: The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; ?-cyclodextrin; ocyclodextrin; hydroxypropyl-?-cyclodextrin; sulfobutylether-?-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.Type: GrantFiled: April 12, 2019Date of Patent: January 28, 2020Assignee: ONCOPEPTIDES ABInventors: Jack Spira, Fredrik Lehmann
-
Patent number: 10539551Abstract: A previously unrecognized fundamental property of ?1PI is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified ?1PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with Human Immunodeficiency Virus-1 (HIV-1) infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of ?1PI with its receptors, cell surface Human Leucocyte Elastase (HLEcs) and Lipoprotein Receptor-related Protein (LRP), influences the level of cells of different lineages. Genetic and proteolytic modification of ?1PI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.Type: GrantFiled: April 3, 2017Date of Patent: January 21, 2020Assignees: The Institute for Human Genetics and BiochemistryInventor: Cynthia L. Bristow
-
Patent number: 10537623Abstract: Provided is a method for inducing immunity for therapy of a cancer(s). The method includes the step of administering to an individual with cancer at least one polypeptide selected from the polypeptides (a) or (b) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at least one polypeptide, the recombinant vector(s) being capable of expressing the polypeptide(s) in vivo: (a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 22, or 24; and (b) a polypeptide having a sequence identity of not less than 95% to the polypeptide (a). Further, an in vitro method for preparing an antigen-presenting cell is provided. The method includes the step of contacting the antigen-presenting cell with the at least one polypeptide selected from: (a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 22, or 24; and (b) a polypeptide having a sequence identity of not less than 95% to the polypeptide (a).Type: GrantFiled: September 29, 2015Date of Patent: January 21, 2020Assignee: TORAY INDUSTRIES, INC.Inventors: Akira Kurihara, Fumiyoshi Okano
-
Patent number: 10519434Abstract: Collection devices and kits for biological sample collection include a biologic sample collection device having a hydrophilic swab matrix that includes a modified polycaprolactone (PCL). Methods of production and use thereof are also described herein. The biologic sample collection devices, kits and methods described herein are used to collect a biologic sample (e.g., blood, buccal cells, etc.) and to enable extraction of nucleic acids (e.g., DNA) from that biologic sample so that the nucleic acids can be analyzed (e.g., sequencing and subsequent analyses of DNA).Type: GrantFiled: July 17, 2017Date of Patent: December 31, 2019Inventors: Jeff Morhet, Thomas Kindt, Franco Ferrari, Vasana Maneeratana, Frederic Zenhausern, Sean Grandfield, Beverly L. Wolgast, Alistair McIntyre
-
Patent number: 10517925Abstract: Provided are a composition including a Kang AI 1 (KAI1) polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a use thereof, and more specifically, a composition including a KAI1 polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a pharmaceutical composition for preventing and treating cancer. Further, KAI1, which is expressed in a pericyte rather than in an endotheliocyte, can inhibit angiogenesis by functioning as a negative angiogenic regulator, and thus the subject matter can inhibit angiogenesis due to a known angiogenesis factor by various methods such as a method using a supernatant in a pericyte which forcefully increases KAI1 or in which KAI1 is forcefully increased, a method using a KAI1 protein, or a method for inhibiting a Src-Pkc pathway provoking the degradation of KAI1. Further, the subject matter can identify the severity of a cancer patient by identifying the expression of KAI1 in a pericyte.Type: GrantFiled: May 4, 2016Date of Patent: December 31, 2019Assignee: SEOUL NATIONAL UNIVERSITY R & DB FOUNDATIONInventors: Hyo-Soo Kim, Jin Hur, Jae Il Choi
-
Patent number: 10507242Abstract: The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a Transforming Growth Factor beta (TGF?) antagonist in combination with capecitabine and ixabepilone to treat breast cancer.Type: GrantFiled: January 9, 2017Date of Patent: December 17, 2019Assignee: GENZYME CORPORATIONInventors: Jay Harper, Scott Lonning, Frank Hsu
-
Patent number: 10500283Abstract: The present investigation relates to entrapment of carbohydrate antigen such as Vi polysaccharide of Salmonella typhi in poly (DL) lactide (PDLLA) and polylactide-co-glycolide (PLGA) polymer particles. The formulated product not only elicits primary antibody titers from single dose application but also evokes memory antibody titer against the T independent antigen.Type: GrantFiled: May 29, 2012Date of Patent: December 10, 2019Assignee: National Institute of ImmunologyInventors: Anish Chakkumkal, Amulya Kumar Panda
-
Patent number: 10500227Abstract: Echogenic liposomes (ELIP) formulated with an at least partially pegylated phospholipid bi-layer shell, encapsulated nitric oxide, and encapsulated perfluorocarbon of the formula CxFy in a ratio of about 1:1 by volume, wherein X is greater than or equal to 3, are disclosed, along with methods for treating a patients suffering from cardiovascular disease by administering the ELIP at a site remote from the target diseased section, monitoring presence of the ELIP at the target diseased section, and administering ultrasound upon detection of presence such that bioactive NO is released at the target diseased section.Type: GrantFiled: December 3, 2015Date of Patent: December 10, 2019Assignee: University of CincinnatiInventors: Christy Holland, Jason Raymond, Jonathan Sutton
-
Patent number: 10494412Abstract: The present invention relates to novel peptides, which impair PBX-dependent regulation of gene transcription and thus have utility in the treatment or prevention of disorders in which aberrant cell division occurs.Type: GrantFiled: October 20, 2016Date of Patent: December 3, 2019Assignee: HOX THERAPEUTICS LIMITEDInventor: Richard Morgan
-
Patent number: 10485858Abstract: Provided herein are cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. Also contained herein are regimens by which cancer stem cell targeted cancer vaccines are administered, such regimens comprising peptides, compositions, immunomodulatory agents, and emulsifiers. Also provided are the patient populations to which the regimens are to be administered, and the dosages, schedules, route of administration for the regimens.Type: GrantFiled: May 15, 2013Date of Patent: November 26, 2019Assignee: Stemline Therapeutics, Inc.Inventors: Ivan Bergstein, Christopher Brooks, Thomas P. Cirrito
-
Patent number: 10478470Abstract: The present invention relates to a pharmaceutical composition containing leuprolide acetate and having both immediate and sustained release properties and, more specifically, to a pharmaceutical composition in which, on the basis of the total weight of active ingredients, leuprolide as an immediate release preparation is contained in 0.001 wt % to 25 wt %; and leuprolide contained in microspheres of a sustained release preparation is contained in 75 wt % to 99.999 wt %. The pharmaceutical composition of the present invention is characterized by satisfying both a drug immediate release property so as to realize the prompt exposure to a sufficient amount of drug at the early stage for expression of medicinal effects and a drug sustained release property for four weeks or longer, and the pharmaceutical composition is effective in the prevention and treatment of sex hormone-dependent positive or malignant diseases.Type: GrantFiled: January 27, 2017Date of Patent: November 19, 2019Assignee: SK CHEMICALS CO., LTD.Inventors: Hong Kee Kim, Kyu Ho Lee, Seok Hyun Hong, Yong-kyu Kwak, Ho Chul Shin, Hun-Teak Kim
-
Patent number: 10471016Abstract: The invention relates to microparticles comprising a crosslinked gel and methods for making and using same.Type: GrantFiled: March 8, 2018Date of Patent: November 12, 2019Assignee: President and Fellows of Harvard CollegeInventors: David J. Mooney, David A. Weitz, Stefanie Utech, Radivoje Prodanovich, Esther Amstad, Raluca Ostafe, Angelo S. Mao, Connie Chang Wilking, Huanan Wang
-
Patent number: 10472395Abstract: Provided are cyclic peptide analogs, conjugates comprising such compounds, and pharmaceutical compositions comprising such compounds and conjugates, and methods of treating cancer with such compounds and conjugates.Type: GrantFiled: March 3, 2016Date of Patent: November 12, 2019Assignee: Sirenas LLCInventors: Venkat Rami Reddy Macherla, Alexander Wayne Schammel, Ippei Usui, Elizabeth Paige Stout, Jacob Neal Beverage, Bryan Junn Lee, Steven Bruce Cohen
-
Patent number: 10463725Abstract: Provided is a method for inducing immunity for therapy of a cancer(s). The method includes the step of administering to an individual with cancer at least one polypeptide selected from the polypeptides (a) or (b) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at least one polypeptide, the recombinant vector(s) being capable of expressing the polypeptide(s) in vivo: (a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 8, 10 and 12; and (b) a polypeptide having a sequence identity of not less than 95% to the polypeptide (a).Type: GrantFiled: October 13, 2015Date of Patent: November 5, 2019Assignee: TORAY INDUSTRIES, INC.Inventors: Akira Kurihara, Fumiyoshi Okano
-
Patent number: 10434047Abstract: A microcapsule composition comprising at least one polymer substantially disposed as a semi-permeable shell around an aqueous buffered solution and at least one agent, wherein the agent permeates the shell, and wherein the composition is suitable for delivery to a mammal.Type: GrantFiled: December 3, 2018Date of Patent: October 8, 2019Assignee: Premier Dental Products CompanyInventors: Mark A. Latta, Stephen M. Gross, William A. McHale